Gastroenterology Archives - Insights

Genetic Testing for Pancreatitis

MCL Education — Wed, 03 Sep 2025 10:00:00 +0000

Register now – Nov. 12, 2025 - PACE/State of FL - Review known genetic predisposing factors to acute or chronic pancreatitis, as well as define who may benefit from genetic testing.

The post Genetic Testing for Pancreatitis appeared first on Insights.

Expanded Assay Better Identifies Hereditary Pancreatitis: Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC

Barbara J. Toman — Tue, 15 Jul 2025 13:00:00 +0000

Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC, explain how Mayo Clinic Laboratories' expanded test panel captures rarer as well as more common genetic causes of hereditary pancreatitis. That information is key to managing patients' enhanced risk for pancreatic cancer.

The post Expanded Assay Better Identifies Hereditary Pancreatitis: Linda Hasadsri, M.D., Ph.D., and Huong Cabral, M.S., CGC appeared first on Insights.

Expanded Pancreatitis Gene Panel (PANGP)

MCL Education — Tue, 08 Jul 2025 12:00:00 +0000

Clinically relevant overview of key genetic factors, testing strategies, and post-result care.

The post Expanded Pancreatitis Gene Panel (PANGP) appeared first on Insights.

Labile Copper Test Enhances Evaluation for Wilson’s Disease: Joshua Bornhorst, Ph.D.

Barbara J. Toman — Tue, 01 Jul 2025 13:00:00 +0000

Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' labile copper assay (Mayo ID: LBCS) improves upon standard blood tests for Wilson's disease. The new assay measures not just overall copper but also the fraction of copper that is bioavailable, or labile bound.

The post Labile Copper Test Enhances Evaluation for Wilson’s Disease: Joshua Bornhorst, Ph.D. appeared first on Insights.

Precision in the pancreas: A new genetic test transforms hereditary pancreatitis diagnosis and care

jgilligan1 — Tue, 24 Jun 2025 13:00:00 +0000

Mayo Clinic Laboratories’ newly expanded Hereditary Pancreatitis Gene Panel is transforming how clinicians diagnose and manage a complex, often elusive disease. Developed through close collaboration between lab scientists, genetic counselors, and clinicians, the test uses a whole exome sequencing backbone to analyze nine carefully selected genes with strong clinical relevance. This focused approach avoids ambiguous results while empowering early diagnosis, cancer risk assessment, and family testing. Built on a whole exome backbone with reflex capabilities, the panel represents a major step forward in precision medicine — offering clarity for patients and providers, and a platform for future genomic innovation.

The post Precision in the pancreas: A new genetic test transforms hereditary pancreatitis diagnosis and care appeared first on Insights.

Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing

Barbara J. Toman — Mon, 21 Oct 2024 13:15:00 +0000

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

The post Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing appeared first on Insights.

Innovative bile acid malabsorption panel transforms gastrointestinal care

Nicole Holman — Mon, 12 Aug 2024 13:00:00 +0000

Mayo Clinic Laboratories has introduced a revolutionary diagnostic test for bile acid malabsorption, a significant contributor to chronic diarrhea. Developed by Dr. Michael Camilleri and Dr. Leslie Donato, this new bile acid malabsorption panel simplifies diagnosis and improves patient care by eliminating the need for special diets or prolonged stool collection. The test's effectiveness has been validated internationally, offering new treatment avenues for patients. Discover how this innovative test is transforming clinical practice and enhancing patient outcomes.

The post Innovative bile acid malabsorption panel transforms gastrointestinal care appeared first on Insights.

Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D.

Barbara J. Toman — Tue, 06 Aug 2024 13:00:00 +0000

Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.

The post Panel Boosts Therapeutic Monitoring of IBD Drug: Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D. appeared first on Insights.

Celiac Disease: Diagnostic Testing Algorithms

MCL Education — Thu, 30 May 2024 12:00:00 +0000

This three-part microlearning series is designed for healthcare professionals interested in understanding the diagnostic algorithms for celiac disease.

The post Celiac Disease: Diagnostic Testing Algorithms appeared first on Insights.

Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D.

Barbara J. Toman — Tue, 16 Apr 2024 13:00:00 +0000

Maria Alice Willrich, Ph.D., explains how Mayo Clinic Laboratories' new assay provides therapeutic drug monitoring of risankizumab, or RISA. Test results help guide care for patients with plaque psoriasis, psoriatic arthritis, and Crohn's disease.

The post Assay monitors response to monoclonal antibody therapy: Maria Alice Willrich, Ph.D. appeared first on Insights.